{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T07:29:50Z","timestamp":1790666990139,"version":"4.1.0"},"reference-count":23,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"23","content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["JCO"],"published-print":{"date-parts":[[2016,8,10]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Cancer cells can exploit the programmed death-1 (PD-1) immune checkpoint pathway to avoid immune surveillance by modulating T-lymphocyte activity. In part, this may occur through overexpression of PD-1 and PD-1 pathway ligands (PD-L1 and PD-L2) in the tumor microenvironment. PD-1 blockade has produced significant antitumor activity in solid tumors, and similar evidence has emerged in hematologic malignancies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this phase I, open-label, dose-escalation, cohort-expansion study, patients with relapsed or refractory B-cell lymphoma, T-cell lymphoma, and multiple myeloma received the anti\u2013PD-1 monoclonal antibody nivolumab at doses of 1 or 3 mg\/kg every 2 weeks. This study aimed to evaluate the safety and efficacy of nivolumab and to assess PD-L1\/PD-L2 locus integrity and protein expression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Eighty-one patients were treated (follicular lymphoma, n = 10; diffuse large B-cell lymphoma, n = 11; other B-cell lymphomas, n = 10; mycosis fungoides, n = 13; peripheral T-cell lymphoma, n = 5; other T-cell lymphomas, n = 5; multiple myeloma, n = 27). Patients had received a median of three (range, one to 12) prior systemic treatments. Drug-related adverse events occurred in 51 (63%) patients, and most were grade 1 or 2. Objective response rates were 40%, 36%, 15%, and 40% among patients with follicular lymphoma, diffuse large B-cell lymphoma, mycosis fungoides, and peripheral T-cell lymphoma, respectively. Median time of follow-up observation was 66.6 weeks (range, 1.6 to 132.0+ weeks). Durations of response in individual patients ranged from 6.0 to 81.6+ weeks.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Nivolumab was well tolerated and exhibited antitumor activity in extensively pretreated patients with relapsed or refractory B- and T-cell lymphomas. Additional studies of nivolumab in these diseases are ongoing.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1200\/jco.2015.65.9789","type":"journal-article","created":{"date-parts":[[2016,6,6]],"date-time":"2016-06-06T23:44:07Z","timestamp":1465256647000},"page":"2698-2704","update-policy":"https:\/\/doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":918,"title":["Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study"],"prefix":"10.1200","volume":"34","author":[{"given":"Alexander M.","family":"Lesokhin","sequence":"first","affiliation":[{"name":"Alexander M. Lesokhin and Deepika Cattry, Memorial Sloan Kettering Cancer Center; Alexander M. Lesokhin, Weill Cornell Medical College, New York, NY; Stephen M. Ansell, Mayo Clinic, Rochester, MN; Philippe Armand, Bjoern Chapuy, Gordon J. Freeman, Scott J. Rodig, and Margaret A. Shipp, Dana-Farber Cancer Institute; David Avigan, Beth Israel Deaconess Medical Center; Azra H. Ligon and Scott J. Rodig, Brigham and Women\u2019s Hospital, Boston, MA; Emma C. Scott, Oregon Health & Science University Knight Cancer..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen M.","family":"Ansell","sequence":"additional","affiliation":[{"name":"Alexander M. Lesokhin and Deepika Cattry, Memorial Sloan Kettering Cancer Center; Alexander M. Lesokhin, Weill Cornell Medical College, New York, NY; Stephen M. Ansell, Mayo Clinic, Rochester, MN; Philippe Armand, Bjoern Chapuy, Gordon J. Freeman, Scott J. Rodig, and Margaret A. Shipp, Dana-Farber Cancer Institute; David Avigan, Beth Israel Deaconess Medical Center; Azra H. Ligon and Scott J. Rodig, Brigham and Women\u2019s Hospital, Boston, MA; Emma C. Scott, Oregon Health & Science University Knight Cancer..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Armand","sequence":"additional","affiliation":[{"name":"Alexander M. Lesokhin and Deepika Cattry, Memorial Sloan Kettering Cancer Center; Alexander M. Lesokhin, Weill Cornell Medical College, New York, NY; Stephen M. Ansell, Mayo Clinic, Rochester, MN; Philippe Armand, Bjoern Chapuy, Gordon J. Freeman, Scott J. Rodig, and Margaret A. Shipp, Dana-Farber Cancer Institute; David Avigan, Beth Israel Deaconess Medical Center; Azra H. Ligon and Scott J. Rodig, Brigham and Women\u2019s Hospital, Boston, MA; Emma C. Scott, Oregon Health & Science University Knight Cancer..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma C.","family":"Scott","sequence":"additional","affiliation":[{"name":"Alexander M. Lesokhin and Deepika Cattry, Memorial Sloan Kettering Cancer Center; Alexander M. Lesokhin, Weill Cornell Medical College, New York, NY; Stephen M. Ansell, Mayo Clinic, Rochester, MN; Philippe Armand, Bjoern Chapuy, Gordon J. Freeman, Scott J. Rodig, and Margaret A. Shipp, Dana-Farber Cancer Institute; David Avigan, Beth Israel Deaconess Medical Center; Azra H. Ligon and Scott J. Rodig, Brigham and Women\u2019s Hospital, Boston, MA; Emma C. Scott, Oregon Health & Science University Knight Cancer..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad","family":"Halwani","sequence":"additional","affiliation":[{"name":"Alexander M. Lesokhin and Deepika Cattry, Memorial Sloan Kettering Cancer Center; Alexander M. Lesokhin, Weill Cornell Medical College, New York, NY; Stephen M. Ansell, Mayo Clinic, Rochester, MN; Philippe Armand, Bjoern Chapuy, Gordon J. Freeman, Scott J. Rodig, and Margaret A. Shipp, Dana-Farber Cancer Institute; David Avigan, Beth Israel Deaconess Medical Center; Azra H. Ligon and Scott J. Rodig, Brigham and Women\u2019s Hospital, Boston, MA; Emma C. Scott, Oregon Health & Science University Knight Cancer..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Gutierrez","sequence":"additional","affiliation":[{"name":"Alexander M. Lesokhin and Deepika Cattry, Memorial Sloan Kettering Cancer Center; Alexander M. Lesokhin, Weill Cornell Medical College, New York, NY; Stephen M. Ansell, Mayo Clinic, Rochester, MN; Philippe Armand, Bjoern Chapuy, Gordon J. Freeman, Scott J. Rodig, and Margaret A. Shipp, Dana-Farber Cancer Institute; David Avigan, Beth Israel Deaconess Medical Center; Azra H. Ligon and Scott J. Rodig, Brigham and Women\u2019s Hospital, Boston, MA; Emma C. Scott, Oregon Health & Science University Knight Cancer..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael M.","family":"Millenson","sequence":"additional","affiliation":[{"name":"Alexander M. Lesokhin and Deepika Cattry, Memorial Sloan Kettering Cancer Center; Alexander M. Lesokhin, Weill Cornell Medical College, New York, NY; Stephen M. Ansell, Mayo Clinic, Rochester, MN; Philippe Armand, Bjoern Chapuy, Gordon J. Freeman, Scott J. Rodig, and Margaret A. Shipp, Dana-Farber Cancer Institute; David Avigan, Beth Israel Deaconess Medical Center; Azra H. Ligon and Scott J. Rodig, Brigham and Women\u2019s Hospital, Boston, MA; Emma C. Scott, Oregon Health & Science University Knight Cancer..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam D.","family":"Cohen","sequence":"additional","affiliation":[{"name":"Alexander M. Lesokhin and Deepika Cattry, Memorial Sloan Kettering Cancer Center; Alexander M. Lesokhin, Weill Cornell Medical College, New York, NY; Stephen M. Ansell, Mayo Clinic, Rochester, MN; Philippe Armand, Bjoern Chapuy, Gordon J. Freeman, Scott J. Rodig, and Margaret A. Shipp, Dana-Farber Cancer Institute; David Avigan, Beth Israel Deaconess Medical Center; Azra H. Ligon and Scott J. Rodig, Brigham and Women\u2019s Hospital, Boston, MA; Emma C. Scott, Oregon Health & Science University Knight Cancer..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J.","family":"Schuster","sequence":"additional","affiliation":[{"name":"Alexander M. Lesokhin and Deepika Cattry, Memorial Sloan Kettering Cancer Center; Alexander M. Lesokhin, Weill Cornell Medical College, New York, NY; Stephen M. Ansell, Mayo Clinic, Rochester, MN; Philippe Armand, Bjoern Chapuy, Gordon J. Freeman, Scott J. Rodig, and Margaret A. Shipp, Dana-Farber Cancer Institute; David Avigan, Beth Israel Deaconess Medical Center; Azra H. Ligon and Scott J. Rodig, Brigham and Women\u2019s Hospital, Boston, MA; Emma C. Scott, Oregon Health & Science University Knight Cancer..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Lebovic","sequence":"additional","affiliation":[{"name":"Alexander M. Lesokhin and Deepika Cattry, Memorial Sloan Kettering Cancer Center; Alexander M. Lesokhin, Weill Cornell Medical College, New York, NY; Stephen M. Ansell, Mayo Clinic, Rochester, MN; Philippe Armand, Bjoern Chapuy, Gordon J. Freeman, Scott J. Rodig, and Margaret A. Shipp, Dana-Farber Cancer Institute; David Avigan, Beth Israel Deaconess Medical Center; Azra H. Ligon and Scott J. Rodig, Brigham and Women\u2019s Hospital, Boston, MA; Emma C. Scott, Oregon Health & Science University Knight Cancer..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madhav","family":"Dhodapkar","sequence":"additional","affiliation":[{"name":"Alexander M. Lesokhin and Deepika Cattry, Memorial Sloan Kettering Cancer Center; Alexander M. Lesokhin, Weill Cornell Medical College, New York, NY; Stephen M. Ansell, Mayo Clinic, Rochester, MN; Philippe Armand, Bjoern Chapuy, Gordon J. Freeman, Scott J. Rodig, and Margaret A. Shipp, Dana-Farber Cancer Institute; David Avigan, Beth Israel Deaconess Medical Center; Azra H. Ligon and Scott J. Rodig, Brigham and Women\u2019s Hospital, Boston, MA; Emma C. Scott, Oregon Health & Science University Knight Cancer..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Avigan","sequence":"additional","affiliation":[{"name":"Alexander M. Lesokhin and Deepika Cattry, Memorial Sloan Kettering Cancer Center; Alexander M. Lesokhin, Weill Cornell Medical College, New York, NY; Stephen M. Ansell, Mayo Clinic, Rochester, MN; Philippe Armand, Bjoern Chapuy, Gordon J. Freeman, Scott J. Rodig, and Margaret A. Shipp, Dana-Farber Cancer Institute; David Avigan, Beth Israel Deaconess Medical Center; Azra H. Ligon and Scott J. Rodig, Brigham and Women\u2019s Hospital, Boston, MA; Emma C. Scott, Oregon Health & Science University Knight Cancer..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bjoern","family":"Chapuy","sequence":"additional","affiliation":[{"name":"Alexander M. Lesokhin and Deepika Cattry, Memorial Sloan Kettering Cancer Center; Alexander M. Lesokhin, Weill Cornell Medical College, New York, NY; Stephen M. Ansell, Mayo Clinic, Rochester, MN; Philippe Armand, Bjoern Chapuy, Gordon J. Freeman, Scott J. Rodig, and Margaret A. Shipp, Dana-Farber Cancer Institute; David Avigan, Beth Israel Deaconess Medical Center; Azra H. Ligon and Scott J. Rodig, Brigham and Women\u2019s Hospital, Boston, MA; Emma C. Scott, Oregon Health & Science University Knight Cancer..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azra H.","family":"Ligon","sequence":"additional","affiliation":[{"name":"Alexander M. Lesokhin and Deepika Cattry, Memorial Sloan Kettering Cancer Center; Alexander M. Lesokhin, Weill Cornell Medical College, New York, NY; Stephen M. Ansell, Mayo Clinic, Rochester, MN; Philippe Armand, Bjoern Chapuy, Gordon J. Freeman, Scott J. Rodig, and Margaret A. Shipp, Dana-Farber Cancer Institute; David Avigan, Beth Israel Deaconess Medical Center; Azra H. Ligon and Scott J. Rodig, Brigham and Women\u2019s Hospital, Boston, MA; Emma C. Scott, Oregon Health & Science University Knight Cancer..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gordon J.","family":"Freeman","sequence":"additional","affiliation":[{"name":"Alexander M. Lesokhin and Deepika Cattry, Memorial Sloan Kettering Cancer Center; Alexander M. Lesokhin, Weill Cornell Medical College, New York, NY; Stephen M. Ansell, Mayo Clinic, Rochester, MN; Philippe Armand, Bjoern Chapuy, Gordon J. Freeman, Scott J. Rodig, and Margaret A. Shipp, Dana-Farber Cancer Institute; David Avigan, Beth Israel Deaconess Medical Center; Azra H. Ligon and Scott J. Rodig, Brigham and Women\u2019s Hospital, Boston, MA; Emma C. Scott, Oregon Health & Science University Knight Cancer..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott J.","family":"Rodig","sequence":"additional","affiliation":[{"name":"Alexander M. Lesokhin and Deepika Cattry, Memorial Sloan Kettering Cancer Center; Alexander M. Lesokhin, Weill Cornell Medical College, New York, NY; Stephen M. Ansell, Mayo Clinic, Rochester, MN; Philippe Armand, Bjoern Chapuy, Gordon J. Freeman, Scott J. Rodig, and Margaret A. Shipp, Dana-Farber Cancer Institute; David Avigan, Beth Israel Deaconess Medical Center; Azra H. Ligon and Scott J. Rodig, Brigham and Women\u2019s Hospital, Boston, MA; Emma C. Scott, Oregon Health & Science University Knight Cancer..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepika","family":"Cattry","sequence":"additional","affiliation":[{"name":"Alexander M. Lesokhin and Deepika Cattry, Memorial Sloan Kettering Cancer Center; Alexander M. Lesokhin, Weill Cornell Medical College, New York, NY; Stephen M. Ansell, Mayo Clinic, Rochester, MN; Philippe Armand, Bjoern Chapuy, Gordon J. Freeman, Scott J. Rodig, and Margaret A. Shipp, Dana-Farber Cancer Institute; David Avigan, Beth Israel Deaconess Medical Center; Azra H. Ligon and Scott J. Rodig, Brigham and Women\u2019s Hospital, Boston, MA; Emma C. Scott, Oregon Health & Science University Knight Cancer..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lili","family":"Zhu","sequence":"additional","affiliation":[{"name":"Alexander M. Lesokhin and Deepika Cattry, Memorial Sloan Kettering Cancer Center; Alexander M. Lesokhin, Weill Cornell Medical College, New York, NY; Stephen M. Ansell, Mayo Clinic, Rochester, MN; Philippe Armand, Bjoern Chapuy, Gordon J. Freeman, Scott J. Rodig, and Margaret A. Shipp, Dana-Farber Cancer Institute; David Avigan, Beth Israel Deaconess Medical Center; Azra H. Ligon and Scott J. Rodig, Brigham and Women\u2019s Hospital, Boston, MA; Emma C. Scott, Oregon Health & Science University Knight Cancer..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph F.","family":"Grosso","sequence":"additional","affiliation":[{"name":"Alexander M. Lesokhin and Deepika Cattry, Memorial Sloan Kettering Cancer Center; Alexander M. Lesokhin, Weill Cornell Medical College, New York, NY; Stephen M. Ansell, Mayo Clinic, Rochester, MN; Philippe Armand, Bjoern Chapuy, Gordon J. Freeman, Scott J. Rodig, and Margaret A. Shipp, Dana-Farber Cancer Institute; David Avigan, Beth Israel Deaconess Medical Center; Azra H. Ligon and Scott J. Rodig, Brigham and Women\u2019s Hospital, Boston, MA; Emma C. Scott, Oregon Health & Science University Knight Cancer..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Brigid","family":"Bradley Garelik","sequence":"additional","affiliation":[{"name":"Alexander M. Lesokhin and Deepika Cattry, Memorial Sloan Kettering Cancer Center; Alexander M. Lesokhin, Weill Cornell Medical College, New York, NY; Stephen M. Ansell, Mayo Clinic, Rochester, MN; Philippe Armand, Bjoern Chapuy, Gordon J. Freeman, Scott J. Rodig, and Margaret A. Shipp, Dana-Farber Cancer Institute; David Avigan, Beth Israel Deaconess Medical Center; Azra H. Ligon and Scott J. Rodig, Brigham and Women\u2019s Hospital, Boston, MA; Emma C. Scott, Oregon Health & Science University Knight Cancer..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret A.","family":"Shipp","sequence":"additional","affiliation":[{"name":"Alexander M. Lesokhin and Deepika Cattry, Memorial Sloan Kettering Cancer Center; Alexander M. Lesokhin, Weill Cornell Medical College, New York, NY; Stephen M. Ansell, Mayo Clinic, Rochester, MN; Philippe Armand, Bjoern Chapuy, Gordon J. Freeman, Scott J. Rodig, and Margaret A. Shipp, Dana-Farber Cancer Institute; David Avigan, Beth Israel Deaconess Medical Center; Azra H. Ligon and Scott J. Rodig, Brigham and Women\u2019s Hospital, Boston, MA; Emma C. Scott, Oregon Health & Science University Knight Cancer..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"Borrello","sequence":"additional","affiliation":[{"name":"Alexander M. Lesokhin and Deepika Cattry, Memorial Sloan Kettering Cancer Center; Alexander M. Lesokhin, Weill Cornell Medical College, New York, NY; Stephen M. Ansell, Mayo Clinic, Rochester, MN; Philippe Armand, Bjoern Chapuy, Gordon J. Freeman, Scott J. Rodig, and Margaret A. Shipp, Dana-Farber Cancer Institute; David Avigan, Beth Israel Deaconess Medical Center; Azra H. Ligon and Scott J. Rodig, Brigham and Women\u2019s Hospital, Boston, MA; Emma C. Scott, Oregon Health & Science University Knight Cancer..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Timmerman","sequence":"additional","affiliation":[{"name":"Alexander M. Lesokhin and Deepika Cattry, Memorial Sloan Kettering Cancer Center; Alexander M. Lesokhin, Weill Cornell Medical College, New York, NY; Stephen M. Ansell, Mayo Clinic, Rochester, MN; Philippe Armand, Bjoern Chapuy, Gordon J. Freeman, Scott J. Rodig, and Margaret A. Shipp, Dana-Farber Cancer Institute; David Avigan, Beth Israel Deaconess Medical Center; Azra H. Ligon and Scott J. Rodig, Brigham and Women\u2019s Hospital, Boston, MA; Emma C. Scott, Oregon Health & Science University Knight Cancer..."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-13-0855"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-10-2660"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-04-216671"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2015.1"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-05-282780"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-10-535443"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0000000000000297"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1411087"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-10-051482"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3239"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.2217\/imt.14.9"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1200690"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1200694"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1302369"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)60958-2"},{"key":"B18","volume-title":"Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0; US Department of Health and Human Services","author":"National Cancer Institute","year":"2009"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-15-0116"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.09.2403"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-10-299487"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.32.0630"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1112824"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1111\/imr.12233"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-09-1339"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.2015.65.9789","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,29]],"date-time":"2022-05-29T06:33:50Z","timestamp":1653806030000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2015.65.9789"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8,10]]},"references-count":23,"journal-issue":{"issue":"23","published-print":{"date-parts":[[2016,8,10]]}},"alternative-id":["10.1200\/JCO.2015.65.9789"],"URL":"https:\/\/doi.org\/10.1200\/jco.2015.65.9789","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.726406639.793539738","asserted-by":"object"}]},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,8,10]]},"assertion":[{"value":"2016-06-06","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}